西斯碳酸盐复合物.西斯碳酸盐复合物. 对吸收的影响,抗瘤特性和毒性
Corey R Centerwall1, Jerry Goodisman, Deborah J Kerwood
1Department of Chemistry, Syracuse University, CST 1-014, Syracuse, New York 13244-4100, USA.
Journal of the American Chemical Society
|September 15, 2005
概括
西斯与生物流体中的碳酸盐发生反应,形成单和双碳酸盐复合物. 这些物种可能会影响思思丁.
科学领域:
- 无机化学 无机化学 有机化学
- 药用化学 医学化学
- 生物化学 生物化学
背景情况:
- 西斯是一种广泛使用的基于的化疗药物.
- 培养基和血液中含有碳酸盐离子.
- 了解西斯在生物环境中的反应性至关重要.
研究的目的:
- 为了研究水化与碳酸盐的反应产物.
- 在生理条件下描述碳酸盐物种的形成.
- 探索这些物种对西斯的治疗疗效的潜在影响.
主要方法:
- 研究了水合思与碳酸盐的反应动力学.
- 形成的中间和最终复合物的特征.
- 与癌症治疗相关的模拟生理条件.
主要成果:
- 最初的反应产生了一种单单碳酸.
- 长时间暴露于碳酸盐会导致二碳酸盐复合物的形成.
- 这些碳酸盐复合体是在模拟的治疗条件下形成的.
结论:
- 碳酸盐物种的形成是生物介质中西斯的重要反应途径.
- 这些物种可能会影响西斯的细胞吸收和分布.
- 改变的物种可能会影响西斯的抗瘤活性和毒性概况.
相关概念视频
Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


